MetaVia's DA-1726 Phase 1 Data Show Promise in Metabolic Disease
Event summary
- MetaVia's DA-1726 demonstrated a 9.8 cm (3.8 inch) statistically significant reduction in waist circumference at Day 54 in a Phase 1b trial.
- The trial showed a 23.7% reduction in liver stiffness (VCTE) by Day 54, suggesting a direct hepatic effect.
- Patients experienced a 9.1% (21.2 lbs) average weight loss and a 12.3 mg/dL reduction in fasted glucose by Day 54.
- The trial, extended to 8 weeks at 48mg, reported no treatment-related discontinuations and mild to moderate gastrointestinal events.
The big picture
The obesity treatment market is experiencing rapid growth driven by the success of GLP-1 receptor agonists, but a significant unmet need remains for therapies that address both weight loss and metabolic dysfunction, particularly non-alcoholic steatohepatitis (MASH). MetaVia's DA-1726, with its dual GLP-1/glucagon receptor agonist mechanism, aims to capture a larger share of this market by offering a more comprehensive solution, but faces competition from established players and emerging dual agonists.
What we're watching
- Titration Risk
- The success of the planned 16-week titration studies, moving to 64mg, will be critical to demonstrating improved tolerability and a competitive advantage over existing GLP-1 therapies.
- Reimbursement
- The company's assertion that DA-1726's glucose-lowering profile without elevations could lead to broader insurance coverage will need to be validated through clinical and economic data.
- Hepatic Impact
- The observed reduction in liver stiffness warrants further investigation to determine if DA-1726 can meaningfully impact MASH progression and become a dual treatment option.
Related topics